Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood.
The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Physicians in the United States, with the exception of New York, may order the test starting today.
Quest developed and validated the laboratory test under an intellectual property license agreement with Envision for use of Envision's proprietary biomarker and immunohistochemistry technology, which includes Envision's unique staining technology and novel biomarkers (named EV1, EV2 and EV3).Recently published data in Pathology shows that 22% of tissue specimens examined with a panel based on the three Envision biomarkers and technology were upgraded, and 20% were downgraded, as compared to the conventional assessment of pathologic evaluation based on hematoxylin and eosin-stained tissue alone
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.